Genflow Biosciences PLC Announces 2024 Highlights
Genflow Biosciences has reported key developments for 2024 in their aging-focused therapeutic programs. The company's MASH program (GF-1002) is advancing to pre-IND phase, partnering with Exothera SA for GMP manufacturing of clinical lots. For Werner Syndrome (GF-1003), they've developed proprietary liver organoids from human patient cells. The Dog Aging program (GF-1004) is initiating a six-month life extension clinical trial in collaboration with Syngene, expected to complete analysis by end of 2025.
Their Sarcopenia program (GF-1005) is progressing with myoblast progenitor studies in partnership with Université libre de Bruxelles, focusing on mitochondrial dysfunction. The company received support from the Belgian Government and has strengthened its research collaborations throughout the year.
Genflow Biosciences ha riportato sviluppi chiave per il 2024 nei loro programmi terapeutici focalizzati sull'invecchiamento. Il programma MASH (GF-1002) dell'azienda sta avanzando verso la fase pre-IND, collaborando con Exothera SA per la produzione GMP di lotti clinici. Per la Sindrome di Werner (GF-1003), hanno sviluppato organoidi epatici proprietari a partire da cellule di pazienti umani. Il programma Dog Aging (GF-1004) sta avviando uno studio clinico di estensione della vita di sei mesi in collaborazione con Syngene, con analisi previste entro la fine del 2025.
Il loro programma per la Sarcopenia (GF-1005) sta progredendo con studi sui progenitori dei mioblasti in partnership con l’Université libre de Bruxelles, concentrandosi sulla disfunzione mitocondriale. L'azienda ha ricevuto supporto dal Governo belga e ha rafforzato le sue collaborazioni di ricerca nel corso dell'anno.
Genflow Biosciences ha informado sobre desarrollos clave para 2024 en sus programas terapéuticos enfocados en el envejecimiento. El programa MASH (GF-1002) de la empresa está avanzando hacia la fase pre-IND, asociándose con Exothera SA para la fabricación GMP de lotes clínicos. Para el Síndrome de Werner (GF-1003), han desarrollado organoides hepáticos propietarios a partir de células de pacientes humanos. El programa de envejecimiento canino (GF-1004) está iniciando un ensayo clínico de extensión de vida de seis meses en colaboración con Syngene, con la expectativa de completar el análisis a finales de 2025.
Su programa de Sarcopenia (GF-1005) está avanzando con estudios sobre progenitores de mioblastos en colaboración con la Université libre de Bruxelles, centrándose en la disfunción mitocondrial. La empresa ha recibido apoyo del Gobierno belga y ha fortalecido sus colaboraciones de investigación a lo largo del año.
Genflow Biosciences는 노화 중심 치료 프로그램의 2024년 주요 개발 내용을 보고했습니다. 회사의 MASH 프로그램(GF-1002)은 pre-IND 단계로 진행 중이며, Exothera SA와 협력하여 임상용 GMP 제조를 진행하고 있습니다. Werner 증후군(GF-1003)에 대해, 그들은 인간 환자 세포로부터 독자적인 간 오르가노이드를 개발했습니다. 개 노화 프로그램(GF-1004)은 Syngene과 협력하여 6개월 생명 연장 임상 시험을 시작하며, 2025년 말까지 분석이 완료될 것으로 예상됩니다.
그들의 근육 감소증 프로그램(GF-1005)은 브뤼셀 자유 대학교와 파트너십을 맺고 미토콘드리아 기능 장애를 중심으로 한 근육세포 전구체 연구를 진행하고 있습니다. 이 회사는 벨기에 정부로부터 지원을 받았으며, 연중 동안 연구 협력을 강화했습니다.
Genflow Biosciences a rapporté des développements clés pour 2024 dans ses programmes thérapeutiques axés sur le vieillissement. Le programme MASH (GF-1002) de l'entreprise progresse vers la phase pré-IND, en partenariat avec Exothera SA pour la fabrication GMP des lots cliniques. Pour le syndrome de Werner (GF-1003), ils ont développé des organoïdes hépatiques propriétaires à partir de cellules de patients humains. Le programme de vieillissement canin (GF-1004) initie un essai clinique d'extension de vie de six mois en collaboration avec Syngene, dont l'analyse devrait être terminée d'ici fin 2025.
Leur programme de sarcopénie (GF-1005) progresse avec des études sur les progéniteurs de myoblastes en partenariat avec l'Université libre de Bruxelles, se concentrant sur la dysfonction mitochondriale. L'entreprise a reçu un soutien du gouvernement belge et a renforcé ses collaborations en recherche tout au long de l'année.
Genflow Biosciences hat wichtige Entwicklungen für 2024 in ihren altersfokussierten Therapeutikprogrammen bekannt gegeben. Das MASH-Programm (GF-1002) des Unternehmens schreitet in die Pre-IND-Phase voran und arbeitet mit Exothera SA an der GMP-Herstellung klinischer Chargen. Für das Werner-Syndrom (GF-1003) haben sie proprietäre Leberorganoide aus menschlichen Patientenzellen entwickelt. Das Hundevergreisungsprogramm (GF-1004) startet eine sechsmonatige klinische Studie zur Lebensverlängerung in Zusammenarbeit mit Syngene, bei der die Analyse bis Ende 2025 abgeschlossen sein soll.
Ihr Sarkopenie-Programm (GF-1005) macht Fortschritte mit Studien zu Myoblasten-Vorstufen in Partnerschaft mit der Université libre de Bruxelles und konzentriert sich auf mitochondriale Dysfunktion. Das Unternehmen erhielt Unterstützung von der belgischen Regierung und hat seine Forschungskooperationen im Laufe des Jahres gestärkt.
- Partnership with Exothera SA for GMP manufacturing capabilities
- Development of proprietary human liver organoids for Werner Syndrome research
- Initiation of dog aging clinical trial with potential partnership opportunities
- Government support from Belgium for research advancement
- No immediate revenue generation from current research programs
- Clinical trial results and full analysis not expected until end of 2025
- Multiple programs in early stages requiring significant capital investment
Genflow Biosciences Plc
("Genflow" or "the Company")
A Look Back at an Exciting 2024
LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / 2024 has been an incredible year for Genflow as we advance our mission to develop novel therapeutics that promote a longer, healthier life.
Our focus on the SIRT6 gene and its potential to slow aging and delay age-related diseases has seen significant progress. This year, we've strengthened our leadership by collaborating with world-class researchers and laboratories, with generous support from the Belgian Government that has been instrumental in advancing our work.
Program Highlights
Throughout the year, our programs made significant strides, including:
MASH (GF-1002): We are advancing to the pre-IND phase of our preclinical development and have partnered with Exothera SA for GMP manufacturing of the clinical lot. Exothera, a specialized CDMO, provides end-to-end GMP manufacturing services for viral vectors, RNA therapeutics and vaccines, with state-of-the-art facilities in Belgium and the US.
Leveraging these innovative technologies and expertise, we are positioned to fast-track our progress and initiate the first proof-of-concept study of our gene therapy in patients with MASH. This milestone is a critical achievement for the Company, signaling our readiness to transition into clinical trials and showcasing the maturity and scalability of our therapeutic platform. Prior to commencing GMP manufacturing, we will ensure full regulatory compliance to reinforce confidence in our program among potential partners, investors, and regulatory agencies.
Werner Syndrome (GF-1003): We have developed a proprietary liver organoid derived from human cells of patients with Werner syndrome. Organoids are miniature, three-dimensional tissue models (grown in the lab) that mimic the structure and function of real organs.
Compared to using animal models, organoids offer several advantages: they are derived from human cells from patients affected with the disease, providing more accurate insights into human-specific biology; they reduce reliance on animals in research; and they allow for personalized disease modeling and drug testing tailored to individual patients.
Dog Aging (GF-1004): We are initiating a life extension clinical trial for aging dogs in collaboration with our contract research partner, Syngene. This six-month study will assess the potential of a veterinary version of our gene therapy to extend both the health span and lifespan of dogs. We expect to complete the full analysis of the trial by the end of 2025. Based on the outcomes, we may explore partnership opportunities or licensing agreements with veterinary specialty pharmaceutical companies.
Sarcopenia (GF-1005): We are making steady progress with our project aimed at addressing mitochondrial dysfunction observed in sarcopenia. This work focuses on restoring mitochondrial health as a key factor in combating the condition. The loading of myoblast progenitors with centSIRT6 is currently underway in collaboration with our partner, Université libre de Bruxelles (ULB). We are optimistic that these efforts will pave the way for innovative solutions to improve muscle health and combat sarcopenia effectively.
Looking Ahead
As we prepare for 2025, we are energized by the progress we've made and the opportunities ahead. Our commitment to tackling aging as a fundamental risk factor for chronic diseases remains steadfast. With continued collaboration and innovation, we are confident we will achieve great things in the coming year.
Thank you all for your trust and support on this journey. Our stakeholders' belief in what we're working towards means the world to us and we can't wait to share more exciting updates in the months to come!
Dr Eric Leire
CEO
Genflow Biosciences Plc.
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
| |
|
|
Corporate Brokers |
| |
Capital Plus Partners Ltd |
| |
|
| |
Jon Critchley, +44 0203 821 6168 |
| |
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on accesswire.com
FAQ
What are the main therapeutic programs in Genflow Biosciences (GENFF) pipeline for 2024?
When will Genflow Biosciences (GENFF) complete the dog aging clinical trial analysis?
What is the partnership between Genflow (GENFF) and Exothera SA for?
What breakthrough has Genflow (GENFF) achieved in Werner Syndrome research?
